Lan J, Lu S, Deng Y, Wen B, Chen H, Wang W et al (2016) Bioinformatics-based Design of

Peptide Vaccine Candidates Targeting Spike Protein of MERS-CoV and immunity analysis in

mice. Bing Du Xue Bao 32:77–81

Mak KK, Pichika MR (2019) Artificial intelligence in drug development: present status and future

prospects. Drug Discov Today 24:773–780

Manica M, Cadow J (2019) Novel AI tools to accelerate cancer research. 11. https://www.ibm.com/

blogs/research/2019/07/ai-tools-for-cancer-research/

Matthews H, Hanison J, Nirmalan N (2016) “Omics”-informed drug and biomarker discovery:

opportunities, challenges and future perspectives. Proteomes

McCall B (2020) COVID-19 and artificial intelligence: protecting healthcare workers and curbing

the spread. Lancet Digit Heal 2:e166–e167

Medicine P (2019) Harnessing the modified proteome for increased diagnostic power, pp 33–39

Michelozzi P, de Donato F, Scortichini M, de Sario M, Noccioli F, Rossi P et al (2020) Mortality

impacts of the coronavirus disease (COVID-19) outbreak by sex and age: rapid mortality

surveillance system, Italy, 1 February to 18 April 2020. Eur Secur 25:2000620

Moutinho-Ribeiro P, Macedo G, Melo SA (2019) Pancreatic cancer diagnosis and management: has

the time come to prick the bubble? Front Endocrinol 9:779

Oskooei A, Born J, Manica M, Subramanian V, Sáez-Rodríguez J, Martínez MR (2018) PaccMann:

prediction of anticancer compound sensitivity with multi-modal attention-based neural

networks. arXiv

Quezada H, Guzmán-Ortiz AL, Díaz-Sánchez H, Valle-Rios R, Aguirre-Hernández J (2017)

Omics-based biomarkers: current status and potential use in the clinic. Boletin Medico del

Hospital Infantil de Mexico 74:219–226

Ricoca Peixoto V, Nunes C, Abrantes A (2020) Epidemic surveillance of Covid-19: considering

uncertainty and under-ascertainment. Port J Public Health 38:23–29

Rovetta A, Bhagavathula AS (2020) COVID-19-related web search behaviors and infodemic

attitudes in Italy: infodemiological study. MIR Public Health Surveill 6:e19374

Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA et al (2006) Survival

advantage from imatinib compared with the combination interferon-α plus cytarabine in

chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

Blood 108:1478–1484

Sandhu R, Gill HK, Sood SK (2016) Smart monitoring and controlling of pandemic influenza a

(H1N1) using social network analysis and cloud computing. J Comput Sci 12:11–22

Seyhan A, Carini C (2014) Biomarkers for drug development: the time is now. In: Carini C,

Menon S, Chang M (eds) Clinical and statistical considerations in personalized medicine.

Chapman & Hall, CRC Press, pp 16–41

Seyhan AA, Carini C (2019) Are innovation and new technologies in precision medicine paving a

new era in patients centric care? J Transl Med 17:114

Shan F, Gao Y, Wang J, Shi W, Shi N, Han M, et al (2020) Lung infection quantification of

COVID-19 in CT images with deep learning. arXiv

Song Y, Jiang J, Wang X, Yang D, Bai C (2020) Prospect and application of internet of things

technology for prevention of SARIs. Clin eHealth 3:1–4

Srinivasa Rao ASR, Vazquez JA (2020) Identification of COVID-19 can be quicker through

artificial intelligence framework using a mobile phone-based survey when cities and towns

are under quarantine. Infect Control Hosp Epidemiol 41:826–830

Steensberg A, Simons TD (2015) Beyond biomarkers in drug discovery and development. Drug

Discov Today 20(3):289–291

Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen LL (2020) Structural basis of SARS-CoV-

2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 10:313–319

The Medical Futurist (2020) https://medicalfuturist.com/how-digital-health-technology-can-help-

manage-the-coronavirus-outbreak/

Vaishya R, Javaid M, Khan IH, Haleem A (2020) Artificial intelligence (AI) applications for

COVID-19 pandemic. Diabetes Metab Syndr Clin Res Rev 14:337–339

14

R. C. Sobti et al.